Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study-Reference-Cited by-同舟云学术

Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study

Published:2012-04-16 Issue:6 Volume:103 Page:1071-1078
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Ohnishi Kazunori¹,Nakaseko Chiaki²,Takeuchi Jin³,Fujisawa Shin⁴,Nagai Tadashi⁵,Yamazaki Hirohito⁶,Tauchi Tetsuzo⁷,Imai Kiyotoshi⁸,Mori Naoki⁹,Yagasaki Fumiharu¹⁰,Maeda Yasuhiro¹¹,Usui Noriko¹²,Miyazaki Yasushi¹³,Miyamura Koichi¹⁴,Kiyoi Hitoshi¹⁵,Ohtake Shigeki¹⁶,Naoe Tomoki¹⁵,

Affiliation:

1. Oncology Center; Hamamatsu University School of Medicine; Hamamatsu

2. Department of Hematology; Chiba University Hospital; Chiba

3. Department of Hematology and Rheumatology; Nihon University School of Medicine; Tokyo

4. Department of Hematology; Yokohama City University Medical Center; Yokohama

5. Division of Hematology; Jichi Medical University Hospital; Shimotsuke

6. Cellular Transplantation Biology; Kanazawa University Graduate School of Medical Science; Kanazawa

7. Department of Hematology; Tokyo Medical University; Tokyo

8. Department of Hematology; Institute for Artificial Organs, Transplantation & Gene Therapy; Sapporo Hokuyu Hospital; Sapporo

9. Department of Hematology; Tokyo Women's Medical University School of Medicine; Tokyo

10. Department of Hematology; International Medical Center; Saitama Medical University; Hidaka

11. Department of Hematology; Kinki University Faculty of Medicine; Osakasayama

12. Division of Oncology and Hematology; Department of Internal Medicine; The Jikei University School of Medicine; Tokyo

13. Atomic Bomb Disease Institute; Nagasaki University Graduate School of Biomedical Sciences; Nagasaki

14. Hematology Division; Japanese Red Cross Nagoya Daiichi Hospital; Nagoya

15. Department of Hematology and Oncology; Nagoya University Graduate School of Medicine; Nagoya

16. Department of Clinical Laboratory Science; Kanazawa University Graduate School of Medical Science; Kanazawa; Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1349-7006.2012.02253.x/fullpdf

Reference27 articles.

1. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N Engl J Med,2006

2. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet;Baccarani;Blood,2006

3. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib;Deininger;Blood,2009

4. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia;Kantarjian;Blood,2006

5. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis;de Lavallade;J Clin Oncol,2008

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Asciminib, a novel allosteric inhibitor of BCR‐ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance;Pharmacology Research & Perspectives;2024-06-21

2. Challenges in management of older patients with chronic myeloid leukemia;Leukemia & Lymphoma;2024-04-23

3. Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group;International Journal of Hematology;2024-04-08

4. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-02

5. CFL1 is Implicated in Chronic Myeloid Leukemia Response during Imatinib Therapy;Journal of Cancer;2024